MedTrace Logo

Trial of Myocet in Metastatic Breast Cancer

NCT00294996 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 363

Last updated 2009-03-31

No results posted yet for this study

Summary

The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.

Conditions

Interventions

DRUG

Myocet

Sponsors & Collaborators

  • Sopherion Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jose Baselga, M.D. · Vall d'Hebron Hospital, Barcelona, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31

Countries

  • United States
  • Argentina
  • Canada
  • Germany
  • India
  • Italy
  • Poland
  • Portugal
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294996 on ClinicalTrials.gov